|
Match
|
Document |
Document Title |
|
|
US20140072624 |
UNIT DOSE FORM FOR ORAL ADMINISTRATION
Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer. |
|
|
US20130095177 |
METHOD OF PREPARING AN ORAL DOSAGE FORM COMPRISING FINGOLIMOD
The present invention relates to a method of preparing an intermediate containing fingolimod, a method of preparing granules containing fingolimod, a method of preparing an oral dosage form... |
|
|
US20140322311 |
CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM
The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one... |
|
|
US20140322318 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the... |
|
|
US20110059170 |
METHODS FOR ADMINISTERING WEIGHT LOSS MEDICATIONS
Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the... |
|
|
US20140065210 |
PROTEIN STABILIZED PROBIOTICS AND PERSONAL CARE PRODUCTS
The present invention relates to a personal care product comprising a protein matrix wherein said protein matrix comprises at least one protein, at least one probiotic and a carrier fluid. The... |
|
|
US20120148671 |
GASTRIC RETAINED GABAPENTIN DOSAGE FORM
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. |
|
|
US20140341983 |
SMART™ SOLID ORAL DOSAGE FORMS
Solid Oral Dosage Forms (SODFs) comprising Self Monitoring and Reporting Therapeutics (SMART™) adherence technology are provided which require no or minimal modification of clinical trial... |
|
|
US20150104509 |
TREATING MUCOSAL LESIONS WITH HYALURONAN DELIVERED FROM AN ADHERING TROCHE
A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis,... |
|
|
US20120207828 |
LARGE DOSE RIBAVIRIN FORMULATIONS
The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg... |
|
|
US20120189693 |
ORAL DOSAGE FORMS
Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0... |
|
|
US20110091545 |
Direct Injection moldable and rapidly disintegrating tablet matrix
The present invention relates to a novel directly compressible matrix for the production of tablets which disintegrate rapidly in the presence of moisture, in particular in the mouth. |
|
|
US20130101670 |
FORMULATIONS COMPRISING COATED FINE PARTICLES
[OBJECT] To provide an intraorally rapidly disintegrating tablet comprising 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxyli
c acid as an active ingredient, which is a formulation that... |
|
|
US20120171286 |
METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF STATIN-INDUCED MYOPATHY
Disclosed are methods for treating or preventing a statin-mediated myopathy in a subject via administration of a therapeutically effective amount of a geranylgeranylation activator. Further... |
|
|
US20140287042 |
Oral Tablet Formulation Consisting Of Fixed Combination Of Rosuvastatin And Ezetimibe For Treatment Of Hyperlipidemia And Cardiovascular Diseases
The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active... |
|
|
US20150250746 |
ACAMPROSATE FORMULATIONS, METHODS OF USING THE SAME, AND COMBINATIONS COMPRISING THE SAME
Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other... |
|
|
US20150017237 |
DOSAGE FORM COMPRISING LOPINAVIR AND RITONAVIR
The present invention relates to an oral dosage form comprising crystalline lopinavir and crystalline ritonavir. The invention further relates to methods of preparing said oral dosage forms... |
|
|
US20150190401 |
ENHANCED BRAIN BIOAVAILABILITY OF GALANTAMINE BY SELECTED FORMULATIONS AND TRANSMUCOSAL ADMINISTRATION OF LIPOPHILIC PRODRUGS
The disclosure relates to selected administration routes for CNS (central nervous system) therapeutics and highly soluble salts, solutions, emulsions or powder formulations thereof, having optimal... |
|
|
US20130280325 |
COMPRESSED SOLID DOSAGE FORMS
This invention relates to compressed solid oral dosage form able to contain a high load of active pharmaceutical ingredient, showing a controlled release profile, and consisting of individual... |
|
|
US20140141078 |
Dissolvable TableT
A dissolvable tablet is disclosed. The tablet includes a front side, an obverse side and a thickness between the front side and the obverse side. The front side and obverse side have a variation... |
|
|
US20140112985 |
METHOD OF PREVENTION AND TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION
This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its... |
|
|
US20140065215 |
CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS OF NITAZOXANIDE
Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is... |
|
|
US20140294952 |
DISSOLVABLE MEDICATION ADMISISTRATION BAG AND METHOD OF USING THE SAME
A dissolvable medication administration bag for the safe and effective crushing and administration of medication to patients who have difficulty swallowing pills is disclosed herein. In some... |
|
|
US20130142870 |
NERAMEXANE MULTIPLE UNIT DOSAGE FORM
Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit... |
|
|
US20130224294 |
DRY PROCESSING OF ATAZANAVIR
The invention relates to dry processes for producing oral dosage forms, more specifically tablets, comprising atazanavir and adhesion enhancers. The invention further relates to compacted... |
|
|
US20140141053 |
MICROLAYER COEXTRUSION TO CREATE A TIME-RELEASE DRUG SUBSTANCE DELIVERY PRODUCT
The present invention relates to medical devices containing time-release drug substance, and more particularly, to medical tubing, catheters, stents, cables (including fiber optic cables), pills,... |
|
|
US20110217372 |
Fast dissolving oral tablets and method for production thereof
Provided is a fast dissolving oral tablet, and a method for the production thereof, including the steps of: compressing a mixture of active ingredients, pharmaceutically acceptable additives, and... |
|
|
US20080175905 |
ESTROGEN/SERM AND ESTROGEN/PROGESTIN BI-LAYER TABLETS
The present invention is directed to bi-layer tablets comprising at least one estrogen in a first layer and a therapeutic agent in a second layer, and processes for their preparation. |
|
|
US20140105971 |
MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA IN HYPERCALCEMIC PATIENTS AND IMPROVED CALCIUM-CONTAINING COMPOSITIONS FOR THE TREATMENT OF HYPERKALEMIA
The present invention relates to novel calcium-containing microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at... |
|
|
US20140294953 |
Abuse-Resistant Formulations
The disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The... |
|
|
US20110091544 |
Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
Small tablets for use in procedural sedation, anxiolysis and analgesia comprising the combination sufentanil and triazolam administered via the oral transmucosal route and methods for using the... |
|
|
US20120135069 |
NANONIZED TESTOSTERON FORMULATIONS FOR IMPROVED BIOAVAILABILITY
Nanonized formulations of testosterone esters, especially testosterone undecanoate, and of testosterone are prepared which show an enhanced oral bioavailability compared to the existing oral... |
|
|
US20130230576 |
MICROLAYER COEXTRUSION TO CREATE A TIME-RELEASE DRUG
Medical devices containing time release drug substance are disclosed, including medical tubing, catheters, stents, cables (including fiber optic cables), pills, capsules, sheaths, threads, clamps,... |
|
|
US20120231075 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix. |
|
|
US20110020444 |
ABUSE-RESISTANT OPIOID DOSAGE FORM
We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix. |
|
|
US20130011474 |
MODIFIED AND IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE
The present invention provides immediate release and modified release oral dosage forms. Specifically, the invention provides modified and immediate release pharmaceutical dosage forms containing... |
|
|
US20110064805 |
Porous cellulose aggregate and molding composition thereof
A porous cellulose aggregate characterized by having a secondary aggregate structure resulting from aggregation of primary cellulose particles, having a pore volume within a particle of 0.265 to... |
|
|
US20110038927 |
CONTROLLED RELEASE HYDROCODONE FORMULATIONS
A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof,... |
|
|
US20120034301 |
TABLET AND PESTLE THEREFOR
A tablet which comprises solid particles, especially magnesium oxide particles as the main component and has excellent shape retentivity with extremely low susceptibility to wearing and chipping.... |
|
|
US20150017236 |
PHARMACEUTICAL COMPOSITIONS OF THYROID HORMONE
Provided herein are methods of stabilizing thyroid hormone, preventing a thyroid hormone from being oxidized, producing a formulation of thyroid hormone having a uniform potency, and reducing the... |
|
|
US20130011476 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface... |
|
|
US20130011475 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface... |
|
|
US20120156292 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface... |
|
|
US20120156291 |
STABLE COMPOSITIONS OF FAMOTIDINE AND IBUPROFEN
Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface... |
|
|
US20120164218 |
SOLID DOSAGE FORMS OF VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE AND METHOD OF MAKING THE SAME
Monolayer, bilayer and trilayer solid dosage forms of a combination of valsartan, amlodipine and hydrochlorothiazide are made. |
|
|
US20120177733 |
SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING THE SAME
Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made. |
|
|
US20100303906 |
SOLID DOSAGE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD OF MAKING SAME
Monolayer and bilayer solid dosage forms of a combination of valsartan and amlodipine are made. |
|
|
US20120183606 |
DRUG DELIVERY SYSTEM COMPRISING POLYOXAZOLINE AND A BIOACTIVE AGENT
The invention relates to drug delivery systems comprising a water-soluble polymer matrix and a bioactive agent entrained therein, said water soluble polymer matrix containing at least 50 wt. % of... |
|
|
US20130156821 |
SOLID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about... |
|
|
US20120195965 |
SOLID DOSAGE FORM COMPRISING A FIBRATE
The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to... |